Extendicare (TSX:EXE) ROCE %: 29.27% (As of Mar. 2026)

What is Extendicare ROCE %?

Extendicare TSX:EXE +0.23% 81 ROCE % is 29.27% as of Mar. 2026. GuruFocus rates TSX:EXE with a GF Score™ of 81/100 and a GF Value™ of C$13.93 (Significantly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Extendicare's annualized ROCE % for the quarter that ended in Mar. 2026 was 29.27%.

Extendicare (TSX:EXE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Extendicare ROCE % Related Terms

Extendicare ROCE % Historical Data

* Premium members only.

The historical data trend for Extendicare's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Extendicare ROCE % Chart

Extendicare Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

5.63

3.08

13.94

27.74

25.73

Extendicare Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															21.96	40.77	31.77	25.63	29.27

81GF Score

Extendicare Inc TSX:EXE

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Extendicare ROCE % Calculation

Extendicare's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	149.637	/	( ( (719.788 - 292.883)	+	(1066.515 - 330.18) )	/ 2 )
	=	149.637	/	( (426.905	+	736.335)	/ 2 )
	=	149.637	/	581.62
	=	25.73 %

Extendicare's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	217.784	/	( ( (1066.515 - 330.18)	+	(1071.251 - 319.716) )	/ 2 )
	=	217.784	/	( ( 736.335	+	751.535 )	/ 2 )
	=	217.784	/	743.935
	=	29.27 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 29.27% mean?

Extendicare (TSX:EXE) has a ROCE % of 29.27% as of Mar. 2026.

Is Extendicare's ROCE % too high?

Extendicare's current ROCE % is 29.27%. The Healthcare Providers & Services industry median ROCE % is 6.41. Extendicare's value of 29.27% is 356.6% above this industry median. Overall, Extendicare has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Extendicare's ROCE % compare to HCA and THC?

Extendicare's ROCE % of 29.27% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Extendicare's value of 29.27% is 356.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Healthcare Providers & Services company?

The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 648 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Extendicare's current ROCE % of 29.27% is 356.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Extendicare's current ROCE % is 29.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Extendicare stock overvalued right now?

Based on GuruFocus' analysis, Extendicare (TSX:EXE) is currently considered Significantly Overvalued. The stock's GF Value™ is C$13.93, compared to a current price of C$34.13 — trading 145% above its estimated fair value. The current ROCE % is 29.27% and 356.6% above the Healthcare Providers & Services industry median of 6.41. Extendicare's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Extendicare (TSX:EXE), the current ROCE % is 29.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Extendicare (TSX:EXE) Overvalued in 2026?

Based on GuruFocus' analysis, Extendicare stock appears to be overvalued. The current stock price of C$34.13 is trading 145% above its estimated GF Value™ of C$13.93. GuruFocus considers Extendicare to be Significantly Overvalued.

Key valuation signals for TSX:EXE:

ROCE %: 29.27%
GF Value™: C$13.93 vs. price of C$34.13 (145% above fair value)
GF Score™: 81/100 with 4 warning signs
Industry Position: 356.6% above the Healthcare Providers & Services median

No single metric tells the full story. See the TSX:EXE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Extendicare Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies TSX:SIA TSX:WELL TSX:DR TSX:AIDX TSX:CRRX TSXV:NPTH TSXV:NLH TSXV:PHA TSXV:ELM HCA XTER:FRE SAU:4013 XKLS:5225 THC BSP:RDOR3 SZSE:300015 DVA NSE:APOLLOHOSP XTER:FME EHC

Other Exchanges EXETF:USA 0S9E:UK 5XE:Germany

Address 3000 Steeles Avenue East, Suite 400, Markham, ON, CAN, L3R 4T9

Website https://www.extendicare.com

Extendicare Inc is a senior care provider in Canada, focused on long-term care and home health care. The has three main business segments: Long-term Care (LTC), Home Health Care, and Managed Services. The Long-term Care segment, operating under the Extendicare brand, represents 53 owned homes in Ontario, Alberta and Manitoba. The Home Health Care segment, operating under the ParaMed brand, provides home health care services annually in Ontario, Alberta, Manitoba and Nova Scotia. The Managed Services segment, operating under the Extendicare Assist and SGP Purchasing Partner Network brands, provides management, consulting and group purchasing services to other care providers across Canada. The majority of the company's revenue is derived from the Long-term Care segment.

81GF Score

Get the complete analysis for TSX:EXE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$34.13

Price

C$13.93

GF Value

View TSX:EXE Analysis

See ROCE % data for all stocks →